Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Sagar Lonial, MD, FACP
Caitlin Costello, MD
Integrating Bispecific Antibodies Into Clinical Practice
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach Into Current and Emerging Management
Kristen Ciombor, MD
James J. Harding, MD
Filippo Pietrantonio, MD
Kanwal Raghav, MD
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
Kathleen Moore, MD, MS
Brad McGregor, MD
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
Susana Banerjee, MBBS, MA, FRCP, PhD
Shubham Pant, MD, MBBS
Targeting HER2 Across Advanced Solid Tumors
Ovarian Cancer: Advances in HER2-Targeted ADCs
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers
Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and Potential Benefits
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.